The evaluation of pharmacoeconomics of thiazolidinedione class of antidiabetic agents-a retrospective study
- At: 2007 FIP Congress in Beijing (China)
- Type: Poster
- By: HUANG, Chiu-Ku (Tainan Municipal Hospital, Tainan, China Taiwan)
- Co-author(s): Wang, Er-Ting (Tainan Municipal Hospital, Tainan, China Taiwan)
Aim: The drugs to ameliorate insulin resistance are PPAR-gï¼ˆperoxisome proliferator-activated receptor-gï¼‰, including rosiglitazone and pioglitazone in Taiwan. The class of hypoglycemic agents was approved to decrease HbA1C, elevate HDL and decrease glucose level in patients with type 2 DM in clinical trials, which following time are about half.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.